Outcomes of COVID-19 in patients with obinutuzumab compared with patients with rituximab: a retrospective cohort study
Abstract Background Patients treated with anti-CD20 monoclonal antibodies could have a higher risk of adverse outcomes of coronavirus disease 2019 (COVID-19). The novel anti-CD20 monoclonal antibody obinutuzumab has shown greater B-cell depletion and superior in vitro efficacy than rituximab. We aim...
| Glavni autori: | , , , , , , , , , , |
|---|---|
| Format: | Članak |
| Jezik: | English |
| Izdano: |
BMC
2024-09-01
|
| Serija: | Virology Journal |
| Teme: | |
| Online pristup: | https://doi.org/10.1186/s12985-024-02484-x |